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Microbial surfactants, so-called biosurfactants, comprise a wide variety of structurally distinct amphi-
pathic molecules produced by several microorganisms. Besides exhibiting surface activity at the inter-
faces, these molecules present powerful characteristics including high biodegradability, low toxicity
and special biological activities (e.g. antimicrobial, antiviral, anticancer, among others), that make them
an alternative to their chemical counterparts. Several medical-related applications have been suggested
for these molecules, including some reports on their potential use in the formulation of nano-sized drug
delivery vectors. However, despite their promises, due to the generalized lack of knowledge on microbial
surfactants phase behavior and stability under diverse physicochemical conditions, these applications
remain largely unexplored, thus representing an exciting ﬁeld of research. These nano-sized vectors
are a powerful approach towards the current medical challenges regarding the development of efﬁcient
and targeted treatments for several diseases. In this review, a special emphasis will be given to nanopar-
ticles and microemulsions. Nanoparticles are very auspicious as their size, shape and stability can be
manipulated by changing the environmental conditions. On the other hand, the easiness of formulation,
as well as the broad possibilities of administration justiﬁes the recent popularity of the microemulsions.
Notwithstanding, both vector types still require further developments to overcome some critical limita-
tions related with toxicity and costs, among others. Such developments may include the search for other
system components, as the microbial surfactants, that can display improved features.
 2015 Elsevier Inc. All rights reserved.1. Introduction
A wide variety of structurally diverse compounds from micro-
bial origin exhibiting surface activity at the interfaces, the so-called
microbial surfactants or biosurfactants, has been reported [1].
These amphipathic compounds resemble the chemical surfactants,
containing both hydrophilic and hydrophobic moieties in the samemolecule. Microbial surfactants can be categorized according to
their mode of action, molecular weight and general physicochem-
ical properties [2,3]. In heterogeneous systems, microbial surfac-
tants form a molecular interfacial ﬁlm that affects the wettability
and surface energy of the original surface. Besides lowering the liq-
uids surface tension, these ﬁlms can also greatly impact the inter-
facial behavior and mass transfer, as they also lower the interfacial
tension between different liquid phases on the interfacial
boundary existing between immiscible phases. Once at interfaces,
the hydrophobic moiety aggregates at the surface facing the
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ented towards the hydrophilic phase (water phase). This property
makes microbial surfactants good foam stabilizers and emulsiﬁers,
which represent the motifs behind their common use as detergents
or food additives. Due to their varied functional properties includ-
ing emulsiﬁcation, wetting, foaming, cleansing and surface activity,
among others, microbial surfactants ﬁnd applications in many
industrial sectors.
Several research efforts have been undertaken to establish the
microbial surfactants as viable alternatives to their chemical
counterparts [1,4–7]. Indeed, microbial surfactants present numer-
ous advantages over the chemical ones, namely regarding their
biodegradability, mild production conditions, environmental com-
patibility, low toxicity, high selectivity and speciﬁc activity at
extreme temperatures, pH and salinities [1]. Moreover, several
potential biomedical therapeutic and prophylactic applications
have been emphasized for these compounds [4–8]. Consequently,
besides their usefulness for chemical and environmental applica-
tions, their unique features have been capturing the attention of
cosmetic, biomedical and pharmaceutical industries [2,9]. Actually,
promising uses of microbial surfactants in the formulation of nano-
sized drug delivery vectors have been reported [5]. It is well known
that the synthesis of stable and effective nanoparticles with well-
deﬁned sizes is still not fully established. Besides, the synthesis
processes are expensive and generally lead to the production of
harmful wastes, thus it is of utmost importance ﬁnding viable
alternative processes [10]. Microbial surfactant-mediated pro-
cesses can be considered as an alternative for the rapid synthesis
of nano-sized materials (particulate dispersions or solid particles
within a size range of 10–1000 nm).
Despite all the advances in the drug delivery science ﬁeld, the
oral bioavailability of a great number of drugs exhibiting poor gas-
trointestinal adsorption remains a challenge [11]. Some strategies
have been pursued towards the development of delivery systems
able to overcome such limitation [12]. The self-emulsifying drug
delivery systems (DDS) constitute a promising example of those
strategies as, besides facilitating adsorption of drugs via intestinal
lymphatic pathways, they have small size, globular shape, solubi-
lize hydrophobic drugs, present formulation advantages and are
easily scalable to industrial setups [13]. Formulations of liquid
self-emulsifying DDS contain oils, surfactants, co-surfactants, and/
or co-solvents. Surfactants are essential for these formulations,
namely they will assist the drug solubilization if used in relatively
large amounts, not only due to the reduced interfacial tension,
but also to the increased permeability of the drugs [14]. An ade-
quate selection of the relative proportions of the formulation com-
ponents is critical to accomplish the desired physicochemical and
pharmaceutical features, such as maximum drug solubilization
capacity, high emulsiﬁcation efﬁciency, acceptable intestinal per-
meability and high drug stability for prolonged periods of time [12].
The use of microbial surfactants in liquid self-emulsifying for-
mulations alternatively to synthetic surfactants represents a very
promising approach that can minimize the toxicity and gastric irri-
tation usually caused by the synthetic surfactants [13]. Indeed,
conventional self-emulsifying DDS commonly contain great
amounts of synthetic surfactants that are recognized to damage
the normal gastric mucosa lining [15]. On the other hand, as men-
tioned, microbial surfactants present high biocompatibility and
low toxicity. Rhamnolipid, surfactin, iturin and pumilacidin are
some of the microbial surfactants generally used for preparing oral
lipid-based formulations of therapeutic agents [5]. For instance,
surfactin has been used to prepare a self-microemulsifying DDS
of vitamin E in order to enhance its pharmaceutical performance.
The referred system exhibited a remarkable increase in the
emulsiﬁcation efﬁciency, dissociation rate, and consequently oral
bioavailability of the therapeutic agent [13].This review discusses the fundamentals of microbial surfactants
as compared to their chemical counterparts, highlighting its poten-
tial applicability as novel nano-sized drug delivery vectors.
2. Microbial versus chemical surfactants
Surfactants are a class of chemical compounds that display
afﬁnity for both aqueous and oily phases, thus possessing both
hydrophilic and hydrophobic properties. A typical surfactant
consists of a lipophilic group, generally a long-chain hydrocarbon
moiety, and a hydrophilic group, which is either a charged or an
uncharged polar group. These molecules tend to migrate to inter-
faces, so that the hydrophilic moiety can stay in the phase with
stronger polarity, and at the same time the lipophilic moiety is
placed in the phase with comparatively weaker polarity,
consequently minimizing the Gibbs energy of the system. This
amphiphilic character is behind the hydrophobic effect, which con-
stitutes the key thermodynamic driving force for surfactant self-
assembly [16]. Distinct classes of surfactants can be deﬁned
according to the charge of their head groups, namely cationic
(positive charge); anionic (negative charge); non-ionic (non-
charged and highly hydrophilic); and zwitterionic (presence of
both negative and positive charge centers, and a net charge equal
to zero).
Similarly, microbial surfactants embrace a set of varied amphi-
pathic molecules with distinct chemical structures that are natu-
rally produced by a number of microorganisms. However, unlike
chemically synthesized surfactants which are classiﬁed by their
head group, microbial surfactants are generally categorized by
their chemical composition and molecular weight, as low (e.g. gly-
colipids and lipopeptides) and high molecular weight (e.g. polysac-
charides, proteins and lipoproteins) surfactants. In general, the
amphiphilic and polyphilic polymers are usually more effective
in stabilizing emulsions, while the low molecular weight microbial
surfactants have simpler structures that lead to good surface active
properties [1,6]. Their hydrophilic moiety is mainly comprised of
an acid, peptide cations, or anions, mono-, di- or polysaccharides,
while their hydrophobic moiety can be an unsaturated or saturated
hydrocarbon chains or fatty acids [2]. The structural orientation of
the molecule on the surfaces and at the interfaces is responsible for
its properties, such as the ability to lower surface and interfacial
tension of liquids and the formation of micelles and microemul-
sions between these different phases. The main types of microbial
surfactants are presented in Table 1. Glycolipids and lipopeptides
are the best-studied microbial surfactants [1]. Examples of glyco-
lipids include rhamnolipids produced by Pseudomonas aeruginosa,
trehalolipids produced by Rhodococcus erythopolis, sophorolipids
produced by Candida bombicola and mannosylerythritol lipids
(MEL) produced by Pseudozyma yeasts, which contain mono- or
disaccharides, combined with long-chain aliphatic acids or
hydroxyaliphatic acids. Among the lipopeptides, examples com-
prise surfactin, iturin and fengicyn cyclic lipopeptides produced
by Bacillus species as antibiotic molecules.
Microbial surfactants, which are mainly formed as secondary
metabolites, have been implicated in the survival of their produc-
ing microorganisms since they facilitate nutrient transport and
uptake, interfere in microbe-host interactions and quorum sensing
mechanisms, and even act as biocide agents [6]. Due to their
diverse chemical structures and surface properties, different
groups of microbial surfactants may display different natural roles
in the producing microorganisms, thus being difﬁcult to generalize
those roles in microbial physiology. The physiological roles of
microbial surface-active compounds have been reviewed by
[22,23]. Some microbial surfactants are essential for the motility
of microorganisms, for example surfactin is crucial for the swarm-
ing motility in Bacillus subtilis. Other microbial surfactants affect
Table 1
Main types of microbial surfactants and their producer microorganisms (adapted from [17–21]).
Class Glycolipids
Type Rhamnolipids (RL) Trehalose lipids (TL) Sophorolipids (SL) Mannosylerythritol lipids (MEL)
Structure
Mono-rhamnolipid
Di-rhamnolipid
Producer Pseudomonas aeruginosa Rhodococcus erithropolis
Arthobacter sp.
Candida bombicola
Candida apicola
Candida antartica
Pseudozyma
Class Lipopeptides
Type Surfactin Iturin Fengycin/plipastatin Lichenysin
Structure
Producer Bacillus subtilis Bacillus subtilis Bacillus subtilis Bacillus licheniformis
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faces. Also, these molecules are involved in cell-to-cell interactions
such as bacterial pathogenesis, quorum sensing and bioﬁlm forma-
tion, maintenance and maturation. For instance, rhamnolipids are
essential to maintain the architecture of the bioﬁlms and are con-
sidered as one of the virulence factors in Pseudomonas sp.
Rhamnolipids, mannosylerythritol lipid and surfactin exhibit anti-
microbial and antibiotic properties thus conferring a competitive
advantage to the microorganism during colonization and cell–cell
competition. Additional roles attributed to microbial surfactants
include cellular differentiation, access to insoluble substrates and
resistance to toxic compounds.
Currently, an intense research activity is being directed towards
the identiﬁcation of new microbial surfactants and characteriza-
tion of their chemical and biological properties. Actually, a great
amount of work on their applications in medical-related ﬁelds
has been encouraged by their accepted potential and biological
nature (reviewed by [5,7]). As previously mentioned, given their
microbial origin, diversity, biodegradability, and low toxicity,
microbial surfactants are considered superior to their chemical
counterparts [6]. Accordingly, their application in the food and cos-
metics industries, enhanced oil recovery and bioremediation has
been broadly investigated [10,24–26].
The microbial surfactants ability to effectively lower the surface
tension of water has been generally recognized. An efﬁcient biosur-
factant can reduce the surface tension of water and air from
72 mN/m to less than 30 mN/m. Surfactin is one of the most pow-
erful microbial surfactants reported, as it can reduce the surface
tension of water to 27 mN/m at a concentration as low as 10 lM
[27]. Likewise, rhamnolipids have been reported to achieve the
same levels of reduction [19]. The sophorolipids from C. bombicola
have been reported to reduce the surface tension to 33 mN/m [28],
while MEL and trehalose lipids to less than 30 mN/m [18,29].
As surfactant monomers are added into solution, the surface
and interfacial tension will decrease until the microbial surfactant
reaches the critical micelle concentration (CMC), i.e. the minimum
concentration necessary to initiate the formation of micelles. At
this concentration, surfactant monomers begin to spontaneously
associate into structured aggregates such as micelles, vesicles or
continuous bilayers. These aggregates are produced as a result of
weak chemical interactions such as hydrophobic, van der Waals
and hydrogen bonding [30,31]. These structures are ﬂuid-like and
can easily move from one state to another as conditions such as
electrolyte concentration and temperature are changed [32]. The
aggregate structure will depend on the polarity of the solvent in
which the surfactant is dissolved. In aqueous solution, the polar
head groups of a micelle will be oriented outward towards the
aqueous phase, while the hydrophobic tails will associate in the
core of the micelle [3]. Efﬁcient surfactants have low CMCs, i.e. less
surfactant is necessary to decrease the surface tension to a given
level. Microbial surfactants are most effective and efﬁcient at their
CMC which can be 10–40 times lower than that of chemical surfac-
tants, thus less surfactant is necessary to get a maximum decrease
in surface tension [2]. Another important feature of microbial sur-
factants for industrial applications is their stability and unaltered
activity when exposed to extreme environmental conditions. Surf-
actin was found to be stable after autoclaving (121 C/20 min),
after 6 months at 18 C, at a pH range from 5 to 11 and NaCl con-
centrations up to 20% [28].
Additionally, microbial surfactants are easily degraded and are
generally considered as low or non-toxic compounds. Ivshina and
co-workers [33] reported concentrations of microbial surfactants
from Rhodococcus spp. and P. aeruginosa strains at which 50% of
their maximal effect (EC50 values) is observed between 50 and
650 mg/l. Moreover, Lima et al. [34] reported EC20 values for differ-
ent microbial surfactants (including lipopeptides and glycolipids)between 261 and 736 mg/l, higher than the obtained for SDS,
25 mg/l. Franzetti and collaborators [35] also reported a low toxic-
ity for the bioemulsiﬁer produced by Variovorax paradoxus 7bCT5
against Vibrio ﬁsheri, with an inhibition of 34 ± 2% after 15 min of
exposure to the highest concentration tested (500 mg/l). Although
the available data on the toxicity of microbial surfactants is limited,
some reports suggest that they are less toxic than their chemical
counterparts. The synthetic anionic surfactant (Corexit) showed a
much higher toxicity than microbial surfactants, as it exhibited an
LC50 (lethal concentration to 50% of test species) against Photobac-
terium phosphoreum at approximately ten times lower concentra-
tions than that for rhamnolipids [28]. Moreover, rhamnolipids
were found to be less toxic than the widely used synthetic surfac-
tant Marlon A-350 [2].
Understanding the functional mechanisms of microbial surfac-
tants is of utmost relevance to develop innovative applications.
Microbial surfactants are known to partition at interfaces of ﬂuid
phases with distinct polarities and hydrogen bonding, thus affect-
ing the adhesion of microorganisms [7]. Also, these molecules can
disrupt cell membranes leading to their lysis [22,36–39]. For
instance, surfactin is known to destabilize membranes disturbing
their integrity and permeability. This is due to changes in the phys-
ical membrane structure or through the disruption of protein con-
formations which alter important membrane functions such as
transport and energy generation [22]. The molecular mechanisms
of surfactin interactions with membrane structures were described
by [40,27]. An important step for membrane destabilization and
leakage is the dimerization of surfactin into the bilayer [41]. The
hypothetical mechanisms of surfactin interactions with mem-
branes involve the insertion into the lipid bilayers, chelating
mono- and divalent cations, modiﬁcation of membrane permeabil-
ity by channel formation or membrane solubilization by a deter-
gent-like mechanism. The incorporation of surfactin into the
membrane leads to dehydration of the phospholipid polar head
groups and the perturbation of lipid packaging which strongly
compromises the bilayer stability, leading to the disturbance of
the membrane barrier properties. These structural instabilities
may explain the primary mode of the antibiotic action, as well as
other important biological effects of this lipopeptide. The extent
of perturbation of the phospholipid bilayer depends on the surfac-
tin concentration. At low concentrations, surfactin penetrates
readily into the cell membrane, where it is completely miscible
with the phospholipids and forms mixed micelles. At moderate
concentrations, the lipopeptide forms domains segregated within
the phospholipid bilayer that may contribute to the formation of
ion-conducting pores in the membrane leading to membrane dis-
ruption and permeabilization at high concentrations. Surfactin
has demonstrated a stronger activity than Triton [42]. Indeed,
microbial surfactants have been recognized by their potent proper-
ties that include antibacterial, antifungal and antiviral activities,
hence making them relevant molecules for uses in medical-related
ﬁelds [4]. Some of these molecules have been suggested as harm-
less and effective substitutes of drugs and antimicrobials. For
instance, these molecules can be used in gene transfection or as
adjuvants for antigens, as well as anti-adhesive coatings for bioma-
terials or incorporated in probiotic preparations for the treatment
and prevention of urogenital infections [4]. In addition, the micro-
bial surfactants have been evaluated for their potential effects
against cancer cells (as reviewed in [5]).
Moreover, several other therapeutic applications have been
advocated for microbial surfactants including novel and striking
uses in nanotechnology mainly based on their ﬂexible self-
assembling [43,44]. Microbial surfactants tend to self-assemble
into hierarchically ordered structures using hydrogen bonding,
hydrophobic and van der Waals interactions [43]. Glycolipids, par-
ticularly MEL, are well known for their self-assembling properties
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groups [45]. Some glycolipids, possessing relatively large hydro-
philic head groups as compared to the hydrophobic part, generally
form micelles in dilute aqueous solutions. Besides spherical
micelles, these surfactants also form disk-like and rod-like struc-
tures [46]. As the surfactant concentration further increases, glyco-
lipid/water systems start to form a range of liquid crystalline
phases. In particular, glycolipid microbial surfactants spontane-
ously self-assemble into a variety of molecular assemblies with
well-deﬁned and/or unique structures, such as sponge (L3), cubic
(V2), hexagonal (H2), or lamellar (La) conﬁgurations [47]. The Fon-
tell scheme (Fig. 1) illustrates the natural sequence of self-assem-
bled structures and phases as a function of the surfactant
concentration [48]. Among these molecular assemblies, vesicles
are the most studied ones. MEL, due to their efﬁcient molecular ori-
entation and effective balance between hydrophilic and hydropho-
bic groups, are able to form giant vesicles with diameters larger
than 10 lm [8]. It is important to mention that the formation of
giant vesicles is not straightforward, since the vesicle structure
requires strictly balanced hydrophobic and hydrophilic groups.
Some synthetic and natural glycolipids bearing a disaccharide or
larger hydrophilic head group have been reported to form vesicular
systems by themselves. However, with the only exception of
rhamnolipids, microbial glycolipids have not been reported to do
the same [8]. Comparatively, rhamnolipids show a pH-sensitive
conversion of molecular assemblies due to the presence of a car-
boxyl group on the side chain. Hence, rhamnolipids form micelles
at pH values higher than 6.8, lipid particles at pH values between
6.2 and 6.6, lamella structures at pH 6.0–6.5, and ﬁnally vesicles
sized 50–100 nm at pH 4.3–5.8. A di-rhamnolipid has been
reported as a bilayer stabilizer in phosphatidylethanolamide (PE)
systems, thus making this molecule a good candidate to form
pH-sensitive vesicles in combination with PE [49]. Glycolipid bio-
surfactant-based vesicles or bilayer membranes appear to be very
promising for exploiting useful nanostructured materials and/or
systems. Examples include the work reported by Maitani and co-
workers [50] that developed a liposome vector containing beta-
sitosterol beta-D-glucoside microbial surfactant-complexed DNA
which was successfully validated for herpes simplex virus thymi-
dine kinase gene therapy. Moreover, nanovectors containing a
microbial surfactant have been shown to greatly increase the efﬁ-
cacy of gene transfection [51]. Additionally, rhamnolipid and surf-
actin have been used to develop biodegradable core–shell
polystyrene/biosurfactant bionanocomposites for protein drug
release using an emulsion polymerization approach [52]. On theReverse 
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Fig. 1. Surfactants self-assembly as a fuother hand, the usefulness of microbial surfactants for the biolog-
ical synthesis of nanoparticles has been described [53,54]. For
example, silver nanoparticles were synthesized using a rapid
microbial surfactant-mediated synthesis [55]. However, although
microbial surfactants are apparently valuable, versatile, multiuse
and handy molecules for therapeutic applications, some of them
may represent a risk for humans and should be cautiously exam-
ined. A simple illustration of this issue is the case of the glycolipids
being produced by P. aeruginosa that present a great potential for
several therapeutic uses, although it is well-known that this strain
is responsible for serious nosocomial infections [56,57].3. Microbial surfactants: properties and phase behavior
Prior knowledge about the features of a system and its compo-
nents through the proper assessment of various parameters such
as the surface properties (i.e. surface and interfacial tensions,
CMC), hydrophilic–lypophilic balance (HLB), Israelachvili–Ninham
packing parameter, P (also called critical packing parameter, CPP)
and Winsor-R ratio would signiﬁcantly reduce the complexity of
a rational choice of the components that can lead to a successful
formulation.3.1. Surface properties
The addition of a surfactant to a given solution will lower its
surface tension due to the surfactant adsorption at the interface.
For a diluted solution, the more molecules adsorb at the interface,
the lower the surface tension of the solution will be. Once the sur-
face adsorption reaches its limit, the unimers in the bulk solution
start to form aggregates as the Gibbs energy required for establish-
ing non-polar chains in contact with water is higher than that of
the repulsive head group interactions, chain packing restrictions
in the aggregate core and creation of the interfacial region, which
are associated with the formation of aggregates. Therefore, aggre-
gation will be thermodynamically favored, and it will be a sponta-
neous and collaborative process. Several forms of surfactant
adsorption and self-aggregation in aqueous solutions have been
reported, however the simplest and most common type of
aggregate formed is the micelle. As previously mentioned, the con-
centration needed to form a micelle is called the CMC. At this point,
the surface tension remains nearly unchanged with increasing sur-
factant concentrations.Hexagonal Micelle
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HLB is a parameter known to affect the stability of an emulsion.
It represents the relative contribution of the hydrophilic and lipo-
philic groups of the surfactant to the emulsion. As a general rule,
low HLB values (3–6) favor the formation of W/O microemulsions
(W – water; O – oil), whereas high HLB values (8–18) favor O/W
microemulsions. For surfactants with very high HLB values
(HLBs > 20), often a co-surfactant is required to reduce their effec-
tive HLB value. The HLB value is only applicable for non-ionic mol-
ecules. For ionic surfactants it has to be calculated experimentally
in a relative basis.
3.3. Critical packing parameter (CPP)
In order to reduce the contact angle of water with hydrocarbon
chains, surfactant molecules tend to form aggregates in solution
with the chains oriented to the interior and enclosed in the aggre-
gate. As mentioned, besides micelles, there are several other types
of aggregates that can be formed. The volume of the hydrophobic
carbon chains relative to the surfactant head group area at the
interface will determine the type of aggregate being formed, as
well as its aqueous behavior [58,59]. The concept of surfactant crit-
ical packing parameter (CPP) is used to illustrate such property.
The packing parameter is signiﬁcantly inﬂuenced by the different
moieties of surfactant and the environmental conditions. There-
fore, it is expected that surfactants exhibiting different CPP will
tend to pack in different ways.
3.4. Spontaneous curvature (Ho)
Alternatively, one can rationalize aggregation on the basis of the
so-called spontaneous curvature, Ho, of the surfactant ﬁlm, i.e. the
preferred mean curvature adopted by the ﬁlm in the absence of
mechanical constraints. Qualitatively, the concept of Ho is similar
to the CPP as the preferred curvature will also depend on the rela-
tive proportion of polar and non-polar volumes. However, the the-
ory behind it is based on the mechanical properties of the ﬁlm as a
whole. Generally, CPP is related with individual molecules, while
Ho is related with a continuum with global physical properties.
3.5. Winsor-R ratio
The ratio of the total interaction energies (per unit area of inter-
face) of the surfactant for the O andW phases is known as theWin-
sor-R ratio. Three possible situations can occur, namely R < 1,
indicating that the water-surfactant interaction is stronger than
the oil-surfactant interaction forming Winsor Type I microemul-
sions; R > 1, suggesting that the strength of oil-surfactant interac-
tion is stronger than the water–surfactant interaction, forming
Winsor Type II microemulsions; and R = 1, representing the situa-
tion in which the interactions are balanced, resulting in the forma-
tion of Winsor Type III microemulsions.4. Microbial surfactants: self-assembly
Self-assembly consists in the ability of surfactant molecules to
self-associate in a given solvent (water and a few other polar sol-
vents), thus forming different types of aggregates and structures
of colloidal dimensions. These structures can be of limited size
(micelles, liposomes and microemulsion droplets) or large with
connectivity in one, two or three dimensions (liquid crystals).
The basic building blocks of all these discrete and inﬁnite struc-
tures can be broadly divided into monolayer-based ﬁlms or
bilayer-based ﬁlms.4.1. Parameters inﬂuencing self-assembly
Similarly to adsorption, the surfactant self-assembly is mainly a
consequence of the hydrophobic effect, although being also inﬂu-
enced by many other factors, including the repulsive interactions
between polar head groups. Using the CPP and Ho parameters it
is possible to qualitatively explain the preferential aggregates
formed (Table 2.). However, the aggregate prediction is only valid
when the interaction between aggregates is rather weak and can
be neglected, which is usually the case for dilute systems. The
structure and dynamics of self-assembled surfactant aggregates
can differ broadly depending not only on the surfactants chemical
structure, but also on the system variables, such as composition
and temperature. The external parameters that strongly inﬂuence
the CPP and Ho, and therefore the type of self-assembled structures
formed, include temperature, salt, co-surfactants, type of oil and
surfactant concentration. Further details on the effect of these
parameters on the formation of the surfactant aggregates can be
found in [16].
4.2. Self-assembled structures and phases
4.2.1. Bulk self-assembly
Depending on the molecular structures of the surfactants, as
well as the abovementioned parameters that affect the CPP and
Ho, a variety of self-organized structures can be formed in solution;
and these are classiﬁed according to their phases as homogeneous
(or single-phase) or heterogeneous (or multiphasic) systems
[58,60].
Homogeneous systems can be further divided as: (a) solutions
(e.g. micellar phase); (b) liquid-crystalline phases (e.g. lamellar
phase); and (c) crystalline phases. Solutions are naturally disor-
dered at both short- and long-range scales, although the existence
of micellar aggregates presumes some degree of molecular organi-
zation in the bulk. Additionally, there is a residual liquid structure
due to spatial correlations between the aggregates. Liquid-crystal-
line phases are disordered at short-range scales but present some
type of orientational order and distinct translational order at
long-range scales. Crystalline phases have both short- and long-
range orders. Heterogeneous systems comprise emulsions, suspen-
sions, foams, gels and adsorbed ﬁlms.
4.2.2. Self-assembly at interfaces
As expected, the surfactant self-assembly does not occur exclu-
sively in the bulk but also at interfaces, such as gas–liquid and
solid–liquid interfaces. Long-chain fatty acids and surfactants,
water-insoluble compounds, can be spread from an organic solvent
on an aqueous solution to form monomolecular ﬁlms adsorbed at
the gas–liquid interface, so-called monolayers. The molecules in
monolayers can be self-organized in different ways, in particular
when they are tightly packed, depending on the lateral forces to
which they are subjected (Table 2.). It is also possible to build mul-
tilayers through successive deposition of monolayer ﬁlms onto a
solid substrate. The deposited ﬁlms are named Langmuir–Blodgett
ﬁlms and are of great relevance for a number of applications (e.g.
biosensors).5. Microbial surfactants applications in nanobiotechnology
The unique properties of microbial surfactants, such as versatile
self-assembling and biochemical properties, which are not usually
observed in conventional chemical surfactants, have been attract-
ing an increased attention in the ﬁeld of bionanotechnology,
namely for the design new functional structures and/or systems.
MEL exhibit the most interesting self-assembling properties and
Table 2
Surfactants self-aggregation structures.
Aggregate Structure CPP Ho
Spherical micelle 1/3 1/R
Cylindrical micelle 1/2 1/2R
Bilayer 1 0
Reverse spherical micelle >1 1/R
Reverse cylindrical micelle >1 1/R
R corresponds to the radii of curvature.
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ied the kinetics of interactions in carbohydrate ligand systems
composed of self-assembled monolayers of MEL-A serving as a
high-afﬁnity, easy to handle and low-cost ligand system from
immunoglobulin G and M and lectins. Igarashi and collaborators
[65] reported that MEL-A signiﬁcantly increased the efﬁciency of
gene transfection mediated by cationic liposomes. Additionally,
Ueno et al. [66] found that MEL-A-containing liposomes exhibited
high activity in DNA encapsulation and membrane fusion with
anionic liposomes, which are important properties for gene trans-
fection. On the other hand, MEL-B- and MEL-C-containing lipo-
somes only increased either the encapsulation or the membrane
fusion. Moreover, the same authors [67] suggested that MEL-A
was capable of increasing and rapidly promoting the transfection
efﬁciency of target cells by inducing membrane fusion between
liposomes and the plasma membrane of these cells. Nanovectors
containing a biosurfactant have been successfully used to increase
the efﬁcacy for gene transfection in vitro and in vivo [51]. State-of-
the-art developments in the nanobiotechnology ﬁeld using micro-
bial surfactants are summarized in Table 3.
Another interesting application of microbial surfactants is the
possibility to synthesize metal-bound nanoparticles using an envi-
ronmentally friendly technology [76]. Moreover, Reddy and collab-
orators [95] synthesized, for the ﬁrst time, surfactin-mediated gold
nanoparticles.
5.1. Microbial surfactants-based liposome vectors and their
applicability for gene transfection
Gene transfection into the cells is of utmost importance for clin-
ical gene therapy [67]. Although several approaches have been
studied for gene transfection, more efﬁcient and safe systems are
still required. Lipofection using cationic liposomes is consideredto be a promising method for introducing foreign genes into the
targeted cells due to their high transfection efﬁciency, low toxicity
and immunogenicity, ease of preparation and targeted application
[70]. The physicochemical properties of cationic liposomes, such as
lipid packing density, shape and zeta potential have a signiﬁcant
effect on gene transfection efﬁciency. As previously discussed,
microbial surfactants hold a number of interesting features that
can be explored in the preparation of those cationic liposome
vectors.
Inoh and co-workers [68] reported that MEL-A promoted DNA
transfection efﬁciency mediated by cationic liposomes. Lipids and
oligonucleotide DNA in MEL-A-containing liposome-DNA complex
were found to distribute in the plasma membrane and nucleus of
the target cells [69], thus suggesting that the biosurfactant induces
the membrane fusion between the target cells and the cationic
liposomes, accelerating the efﬁciency of gene transfection signiﬁ-
cantly. Likewise, Igarashi et al. [65] found that MEL-A signiﬁcantly
increased the efﬁcacy of gene transfection mediated by cationic
liposomes in human cervix carcinoma Hela cells. MEL-liposome
complex was found to be distributed widely in the cytoplasm
and the DNA presence was strongly detected in cytoplasm around
the nucleus. These studies clearly demonstrate that MEL-A is able
to increase gene expression by enhancing the association of the
liposome complexes with the cells, thus suggesting that MEL-A-
containing liposomes could be potentially used as a relevant
non-viral vector for gene transfection and gene therapy.
Ueno et al. [66] found that MEL-A-containing liposomes exhibit
a high DNA encapsulating activity, as well as membrane fusion
with anionic liposomes. Additionally, MEL-B and MEL-C-containing
liposomes only increased either the DNA encapsulation or the
membrane fusion. On another study [67], the same authors further
evaluated the transfection mechanisms mediated by cationic lipo-
somes with NBD-conjugated MEL-A and reported that the biosur-
Table 3
Microbial surfactants applications in nanobiotechnology (adapted from [2]).
Microbial surfactant type Activity/potential application Reference
Mannosylerythritol lipids A Ligand system for immunoglobulin G and M and lectins [47,61–64]
DNA encapsulation and membrane fusion with anionic liposomes [66]
In vitro and in vivo promotion of gene transfection mediated by cationic liposomes [65,67–71]
Delivery of siRNA into the cell cytosol through cationic liposomes [72]
Herpes simplex virus thymidine kinase gene therapy [50]
Stable water-in-oil microemulsions without the addition of a co-surfactant or salt [73]
Increased membrane ﬂuidity of monolayers composed of L-a-dipalmitoylphosphatidylcholine (DPPC) [43]
Self-assembling and of formation of giant vesicles [8]
Mannosylerythritol lipids-B Self-assembling and vesicle-forming activity [73]
Rhamnolipids and sophorolipids Cadmium sulﬁde nanoparticles [74]
Biocompatible microemulsions of lecithin/rhamnolipid/sophorolipid biosurfactants [75]
Rhamnolipids Silver nanoparticles with antibioticmicrobial activity [55]
Nickel oxide nanoparticles by microemulsion technique [76,77]
Silver nanoparticles [78]
ZnS nanoparticles [79]
Stable microemulsions [80–82]
Alcohol-free microemulsions [83]
pH-sensitive vesicles in combination with phosphatidylethanolamide and dioleoylphosphatidylethanolamide [49,84]
Safe adsorption enhancers for oral dugs [85]
Dispersing nanoparticles [86]
Nanozirconia particles [87]
Enhancer of drug release from a lipid-polymer coated hybrid nanoparticle [88]
Sophorolipids Cobalt and silver nanoparticles [89]
Sophorolipid-coated silver and gold nanoparticles with antibacterial activity [90,91]
Rhamnolipids and surfactin Biodegradable core-shell polystyrene/biosurfactant bionanocomposites for protein drug release [52]
Fengycin and surfactin Enhancers for the skin accumulation of aciclovir [92]
Surfactin Cadmium sulﬁde nanoparticles [74]
Surfactin-mediated synthesis of gold nanoparticles [93–95]
Microemulsions of vitamin E [13]
Nanospheres and nanorods brushite particles synthesized in reverse microemulsions of surfactin [96]
Cationic surfactin liposomes enhanced the delivery of siRNA to HeLa cells [97]
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plasma membranes of the target cells, while the cationic liposomes
with MEL-A fused to the plasma membranes. Afterwards, the
authors noted that the DNA released from the vesicles was imme-
diately transferred to the nucleus. Hence, those results suggested
that MEL-A was capable of promoting the transfection efﬁciency
of target cells by inducing membrane fusion between liposomes
and the cells plasma membrane.
In addition, Kitamoto and collaborators [43] demonstrated that
monolayers composed of L-a-dipalmitoylphosphatidylcholine
(DPPC) containing MEL-A had greater membrane ﬂuidity than
those containing only DPPC. Moreover, it was found that the unsat-
urated fatty acids in MEL-A greatly inﬂuenced the surface pressure
and packing density in the monolayer and consequently, the phys-
icochemical properties of MEL-A and MEL-A/lipids [63]. Nanovec-
tors containing MEL-A were further evaluated in vivo regarding
their transfection efﬁciency [71]. When a complex of the nanovec-
tors with MEL-A and plasmid DNA was injected into C57BL/6J mice
bearing B16/BL6 tumors, the biosurfactant signiﬁcantly increased
liposome-mediated gene transfection to the mouse tumor cells.
The transfection efﬁciency of the plasmids into the solid tumors
by the cationic liposomes of cholesteryl-3-beta-carboxyamidoeth-
ylene-N-hydroxyethylamine (OH-Chol) with MEL-A increased by
approximately 100-fold compared to that by the commercially
available DC-Chol cationic liposomes without MEL-A. These results
strongly suggest that non-viral vectors with MEL-A can be success-
fully used for gene transfection in vivo. Nakanishi and collaborators
[51] reviewed the mechanisms of gene delivery by MEL-A based
nanovectors.
The effects of unsaturated fatty acid ratio within the MEL-A bio-
surfactant on the physicochemical properties and gene delivery
into cells of MEL-A based cationic liposomes were further studied
by [70]. The MEL-A (21.5% unsaturated fatty acids)-containing cat-
ionic liposomes induced highly efﬁcient membrane fusion after
addition of anionic liposomes and led to subsequent DNA release.These liposomes were found to fuse with the plasma membrane
and delivered DNA into the nucleus of NIH-3T3 cells. It is impor-
tant to notice that a higher unsaturated fatty acid ratio liposomes
was able to fuse the plasma membrane but did not delivered DNA
into the nucleus, while a lower unsaturated fatty acid ratio lipo-
somes neither fused with the plasma membrane nor delivered
DNA into the nucleus. Therefore, it may be suggested that MEL-A
unsaturated fatty acid ratio signiﬁcantly affects the transfection
efﬁciency due to changes in membrane fusion activity and the efﬁ-
ciency of DNA release from the liposomes. Furthermore, the same
authors [72] suggested that the ability to rapidly and directly deli-
ver siRNA into the cytosol using MEL-A-containing cationic lipo-
somes reduces immune responses, cytotoxicity and other side
effects caused by viral vectors in clinical applications.
On the other hand, MEL B containing a different conﬁguration of
the erythritol moiety has been reported to self-assemble into a
lamellar phase over a wide concentration and temperature range,
while MEL-A self-assembles into various kinds of lyotropic liquid
crystalline phases. Additionally, MEL-B showed great potential as
a vesicle-forming lipid, thus suggesting its potential application
in drug and gene delivery, as well as in transdermal delivery sys-
tems [73].
5.2. Microbial surfactants as auspicious agents for drug delivery
Microbial surfactants, given some of their properties that
include emulsiﬁcation, foaming, detergency and dispersion,
encompass an interesting group of molecules with potential appli-
cation in the ﬁeld of drug delivery [44]. For instance, MEL have
shown a much higher emulsifying activity with soybean oil and
tetradecane than polysorbate 80 [43], as well as an interesting abil-
ity to form stable W/O microemulsions without the addition of a
co-surfactant or salt [73]. On the other hand, it has been reported
that rhamnolipids and sophorolipids can be mixed with lecithins to
prepare biocompatible microemulsions in which the phase
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concentration, thus making them desirable for cosmetic and drug
delivery applications [75]. Rhamnolipid liposomes were patented
as drug delivery systems, useful as microcapsules for drugs, pro-
teins, nucleic acids, dyes and other compounds. These novel lipo-
somes were described as safe and biologically decomposable,
with suitable afﬁnity for biological organisms, stable and with long
service and shelf-life [2]. Furthermore, rhamnolipids have been
reported as safe adsorption enhancers for oral drugs. These micro-
bial surfactants at low concentrations not only enhanced paracel-
lular and transcellular transport pathways in Caco-2 cells
(in vitro model of the human small intestinal epithelium), but also
inhibited P-gp activity. Besides, rhamnolipids showed low toxicity
to Caco-2 cells and erythrocytes [85].
Additionally, the potential of fengycin and surfactin to act as
enhancers for the transdermal penetration and skin accumulation
of aciclovir was evaluated [92]. It was found that these lipopep-
tides did not enhance aciclovir transport across the skin although
they increased aciclovir concentration in the epidermis by a factor
of 2, thus demonstrating the potential of these microbial surfac-
tants for drug delivery applications. Moreover, Onaizi and collabo-
rators [98] studied the micellization and interfacial behavior of a
mixture of surfactin and sodium dodecylbenzylsulphonate and
demonstrated that the formation of mixed micelles was thermody-
namically feasible.
Microemulsions obtained using microbial surfactants are ther-
modynamically stable and their isotropic systems that form spon-
taneously, in addition to their long-term stability, easy
preparation and high solubilization capacity are considered to be
very promising liquid vehicles for future drug delivery systems
[99]. Moreover, microbial surfactants could also be considered as
interesting components of an emulgel, which consists in an emerg-
ing topical drug delivery system. Emulgels are either emulsion of
oil-in-water or water-in-oil type, which is gelled by mixing it with
a gelling agent. The incorporation of an emulsion into a gel
increases its stability and efﬁciency as compared to other topical
drug delivery systems [100].
5.3. Microbial surfactants role in the development and production of
nanoparticles
Nanoparticles are characterized by their unique size and stable
shape [101]. The production of nanoparticles over a wide variety of
physical structures and with high monodispersity still remains a
challenge [10]. Actually, the available techniques are capital inten-
sive, produce hazardous wastes and unstable nanoparticles with
reduced targeted activity. Therefore, clean, non-toxic, size-con-
trolled and environmentally acceptable synthesis procedures are
crucial to encourage the large scale production of nanoparticles
for several applications, including targeted drug delivery and bio-
technology [78,102,103]. Given the need for greener bio-processes
and new synthesis schemes microbial-based, microbial surfactants
are evolving as interesting alternatives for the rapid synthesis of
nanoparticles [89,95,104].
Gold nanoparticles are being increasingly used in the ﬁeld of
drug and gene delivery, targeted therapy and imaging technologies
[105,106]. Potential therapeutic applications of such particles also
include anti-HIV activity, anti-angiogenesis, antimalarial activity,
anti-arthritic activity and biohydrogen production. Similarly, silver
nanoparticles also possess anti-fungal activity, anti-inﬂammatory
effect, anti-viral, anti-angiogenesis and anti-platelet activity [107].
Microbial surfactants canbeused for high-performancenanoma-
terial production, since they easily forma variety of liquid crystals in
aqueous solutions. Reddy and collaborators [95] stabilized the syn-
thesis of silver nanoparticles with surfactin. Besides, these authors
[93] successfully synthesized surfactin-mediatedgoldnanoparticlesand studied the effect of proton concentrations and temperature on
the morphology of the obtained nanoparticles. Nanoparticles syn-
thesized at pH 7 and 9 remained stable for 2 months, while aggre-
gates were observed at pH 5 within 24 h. Moreover, the
nanoparticles formed at pH 7 were uniform in shape and size and
were polydispersed and anisotropic at pH 5 and 9. Nanoparticles
synthesized at room temperature were found to be monodispersed
andweremore uniform as compared to those synthesized at 4 C. In
another study, the authors carried out a biological synthesis of gold
and silver nanoparticles using the bacteria B. subtilis [94]. Gold
nanoparticles were synthesized both intra- and extracellularly,
while silver nanoparticles were exclusively formed extracellularly.
The results suggest that the nanoparticles were stabilized by sur-
face-active molecules, namely surfactin or other biomolecules
released by B. subtilis. Surfactin produced by Bacillus amyloliquefac-
iens KSU-109 was also used for the synthesis of cadmium sulﬁde
nanoparticles which remained stable up to 6 months without com-
promising their functionality [74]. Additionally, Maity and collabo-
rators [96] reported the synthesis of brushite particles (nanospheres
and nanorods) in reverse microemulsions of surfactin.
Rhamnolipids and sophorolipids have also been successfully
used for the synthesis and stabilization of metal-bound nanoparti-
cles. Puriﬁed rhamnolipids from P. aeruginosa strain BS-161R were
used to synthesize silver nanoparticles which exhibited good anti-
biotic activity against both Gram-positive and Gram-negative
pathogens and Candida albicans, thus suggesting their broad spec-
trum antimicrobial activity [55]. In another work, a glycolipid
microbial surfactant produced by Brevibacterium casei MSA19
was used as a stabilizer for the synthesis of stable and uniform sil-
ver nanoparticles [102]. The microbial surfactant acted as a stabil-
ization agent and prevented the formation of aggregates.
Palanisamy and Raichur [76] reported a simple method for syn-
thesizing spherical nickel oxide nanoparticles by microemulsion
technique using rhamnolipids. The synthesized nanoparticles were
found to be fully crystalline and spherical in shape with uniform
distribution and increasing the pH of the solution decreased the
size of the nanoparticles. Xie et al. [78] synthesized silver nanopar-
ticles in rhamnolipid reverse micelles, while in another study
rhamnolipids were used as capping agents for the synthesis of
ZnS nanoparticles in aqueous medium [79].
Sophorolipids have also been evaluated for the synthesis of
nanoparticles and were reported to be good reducing and capping
agents for cobalt and silver particles [89]. Singh and collaborators
[90] proved the antibacterial activity of sophorolipid-coated silver
and gold nanoparticles against both Gram-positive and -negative
bacteria. Furthermore, the authors found that sophorolipid-coated
gold nanoparticles were more cyto and geno-compatible as com-
pared to silver nanoparticles [91].
Methodologies for thebiological synthesis ofmetal nanoparticles
using microbes have been described [94,107,108]. Indeed, several
researchers have recently suggested the usefulness of living cells
andnatural products [81,109–111] in the synthesis of nanoparticles.
For example, Aspergillus fumigatus has been implicated in the extra-
cellular production of silver nanoparticles [112], but many other
fungi andbacteriahavealso been reported toproducegold and silver
nanoparticles, either intra or extracellular [113–118]. Silver nano-
particle synthesis was accomplished using Pseudomonas stutzeri
AG259 [119], Fusarium oxysporum [115], Phanerochaete chrysospori-
um [120], Plectonema boryanum UTEX 485 and Klebsiella pneumonia
[121]. Some of these whole organisms are also able to produce
microbial surfactants, thus contributing to the synthesis process.
5.4. Microbial surfactants as constituents of microemulsion systems
The essential elements to produce a microemulsion-based
colloidal DDS comprise an aqueous phase, an oil phase, a surfactant
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aggregates to form varying structures. These structures are able
to encapsulate and/or solubilize hydrophobic or hydrophilic drugs
in the presence of a dispersed phase (oil for O/W or water for W/O
microemulsions) within its structural core, thus partitioning the
dispersed phase from the continuous phase [122]. A global micro-
emulsion system can exhibit a wide range of structures of diverse
nano-sized geometries (e.g. worm-like, bi-continuous sponge-like,
liquid crystalline, among others). These systems are thermody-
namically stable and exhibit high solubilization capacity and ultra-
low interfacial tensions of oil and water, thus making them
desirable for drug delivery applications [75]. The results from Xie
and collaborators [80] suggest that rhamnolipids could be success-
fully used to form microemulsions using medium chain alcohols as
co-surfactant. Moreover, the phase behavior and microstructure of
these microemulsions were rational to the conformational changes
of rhamnolipid molecules at the interface of O/W [82].
Microemulsion techniques using oil–water-surfactant mixtures
have been found to be very useful in the production of nanoparti-
cles and can be used to synthesize different types of particles. Silver
nanoparticles have been synthesised using a rapidmicrobial surfac-
tant-mediated synthesis, by mixing the surfactant and AgNO3 solu-
tions, followed by NaBH4 and vigorous stirring. Also, the silver
nanoparticle production was accomplished in situ in the W/O
microemulsion phase as described by Xie and collaborators [78].
For that purpose, aqueous solutions of AgNO3, puriﬁed biosurfac-
tant, n-butanol and n-heptane were vigorously stirred until homo-
geneous reverse micelles were formed. Then, NaBH4 was used to
form other reverse micelles. The two reverse micelle solutions were
mixed and afterwards ethanol was added to the reactionmixture to
break the reverse micelles. Finally, the silver nanoparticles were
precipitated from the solution and isolated by centrifugation.
Ramnolipids have been successfully used to synthesize spherical
nickel oxide nanoparticles (NiOnanorods) by this technique [76,77].
A ﬁrstmicroemulsionwas prepared by vigorouslymixing rhamnoli-
pidwith heptane, followed by the addition of NiCl2. A secondmicro-
emulsion was prepared in NH4OH. Subsequently, the two
microemulsions were mixed and stirred to precipitate nickel
hydroxide. The synthesized nanoparticles were found to be stable
at different pH and temperatures [78,95]. Contrarily, experiments
conductedwith a differentmicrobial surfactant (brevifactin, a novel
lipopeptide biosurfactant produced by the marine actinobacterium
Brevibacterium aureumMSA13) showed that both pH and tempera-
ture signiﬁcantly affected the stabilization process [123]. Indeed,
the reduction of metallic ions was found to be sensitive to the pH
as it could affect the shape and size of the nanoparticles. The synthe-
sis occurred under alkaline conditions, which was also reported by
Sanghi and Verma [124].
Rhamnolipids have additionally been reported as dispersants for
nanoparticles [86]. Fatty acids have been suggested to play a double
role in the synthesis of nanoparticles, by stabilizing O/W emulsions
thereby aligning the reducing groups on the outer side; and/or by
reducing metal salts into nanometals [125,126]. Nguyen and Saba-
tini [83] formulated alcohol-free microemulsions using rhamnoli-
pids. Also, microemulsions of lecithin/rhamnolipid/sophorolipid
microbial surfactants using a range of oils have been developed
and evaluated [75]. The sophorolipid played an important role as
the hydrophobic component in these formulations and the phase
behavior of these biocompatible microemulsions did not change
signiﬁcantly with changing temperature and electrolyte concentra-
tion, making them desirable for drug delivery applications.
6. Challenges & future perspectives
One of the present challenges on the medical ﬁeld involves the
search for new drugs and development of DDS with enhancedefﬁcacies capable to signiﬁcantly affect the outcome of several
types of diseases [127]. An ideal DDS must exhibit two key fea-
tures, namely an optimal drug loading capacity, which will lead
to an increased drug bioavailability and ability to reach the target;
and the subsequent release of the drug in a controlled and timely
manner [5]. In this sense, diverse types of drug delivery vectors
have been developed, including polymeric, particulate, macromo-
lecular and cellular carriers. Under the particulate type occurring
in a dispersed colloidal form, several structures can be found com-
prising microspheres, nanoparticles, micelles and liposomes,
among others [128]. Particularly, microemulsions, mainly because
they are easy to formulate, have become popular as new DDS that
can be used through diverse routes including oral, nasal, ocular,
topical and intravenous [127]. Nonetheless, systematic and pre-
clinical studies must be conducted before an optimal formulation
can meet the safety and efﬁcacy criteria required. Given the ther-
modynamic stability of microemulsion systems [129], more cau-
tion has been used in the formulation of self-microemulsifying
DDS, speciﬁcally for oral or parental routes. Indeed, most DDS fail
when these routes of drug administration are used [130], particu-
larly because of the poor efﬁcacy in the drug delivery and the drug
precipitation before it can reach the target site, besides the bio-
compatibility and biodegradability of the materials used.
In the particular case of microemulsions, an increased effort to
search acceptable excipients to be used in the design of safer
microemulsions for drug delivery applications has been registered
lately. Prior attempts have usually applied synthetic hydrocarbon
oils (e.g. heptanes, dodecane and cyclic oils) and surfactants (e.g.
sodium dodecyl sulphate and tetraethylene glycol monododecyl
ether) that are not approved for pharmaceutical applications and
can be toxic [131]. Biocompatibility has been assured by the alter-
native use of lecithins and non-ionic surfactants (e.g. Brijs, Tweens
and AOT) [132]. Simultaneously, a recent trend in the formulation
of microemulsions is to use natural oils and natural and/or micro-
bial surfactants. Natural oils are receiving an increased interest
(e.g. linseed oil, soybean oil, jojoba bean oil, among others), but it
is relatively difﬁcult to solubilize them in microemulsions
[133,134]. Likewise, natural and/or microbial surfactants have
emerged as alternatives to their synthetic counterparts. Particu-
larly, the non-ionic surfactants such as sucrose esters have been
widely used in the production of microemulsions [135,136],
although many other examples can be highlighted. Although the
use of microbial surfactants appears to be an exciting alternative,
these biomolecules also present some limitations that must ﬁrst
be addressed before considering them for drug delivery applica-
tions, for example in what concerns their purity and safety.
Although it is very challenging to predict the nature and stabil-
ity of a microemulsion-based DDS, the current knowledge available
in the literature can support the selection of the most adequate oil/
biosurfactant systems. Similarly to synthetic surfactants, also
microbial surfactants can be affected by the environmental condi-
tions, and thereby their self-assembly. As previously discussed
rhamnolipids and surfactin are the most studied microbial surfac-
tants, thus a great amount of data on their structural aspects at dif-
ferent interfaces and solutions has been reported [137–140].
Nevertheless, microbial surfactants have very complex head
groups which further complicate the accurate evaluation of their
structures, since they can assume diverse structures with only
minor changes in the environment.
In general, it can be anticipated that these microbial surfactants
are non-ionic at low pH values, and anionic at high pH values due
to the presence of carboxylic groups [80]. Moreover, structure tran-
sition from micellar to lamellar upon electrolyte addition has been
reported [141,142]. The possibility of manipulating structure tran-
sition opens a great opportunity for the development of tailored
DDS, as well as for the design of smart DDS that can respond to
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tration) in a controlled way [143].
The aggregation of surfactants in lamellar arrangements can
occur if one of the next conditions is observed [144]. High
surfactant concentrations lead to a lamellar liquid-crystalline
phase, while double-tailed amphiphiles commonly form bilayer
sheets. Upon closing, these sheets form vesicles. Besides, these
aggregates can be obtained from mixtures of anionic and cationic
surfactants in water, mixtures of ionic surfactants and long-chain
alcohols in water, or electrolyte solution. Moreover, in the pres-
ence of high salt concentrations some surfactants in aqueous
solution spontaneously change from micelles to lamellar
aggregates.
The lack of information on microbial surfactant microemulsion
systems, such as phase behavior and its stability under diverse
physicochemical conditions, has limited so far the application of
these molecules in DDS. Nonetheless, an adequate evaluation of
some system parameters such as the HLB, CPP, Ho and Winsor-R
ratio, would greatly assist a rational choice of the components that
ultimately lead to a successful formulation. Additionally, these
parameters constitute powerful tools for the design of drug formu-
lations envisaging a speciﬁc administration route.
In addition to their potential for the formulation of microemul-
sions, microbial surfactants have been suggested as valuable mol-
ecules for the synthesis of nanoparticles and liposomes. Xie and
collaborators [78] reported a promising approach for nanoparticle
synthesis through microemulsion technique involving the use of
an oil–water-surfactant mixture. Despite the high potential of
chemical surfactants, these can present some toxicity to the envi-
ronment and therefore, the possible use of microbial surfactants
represents an interesting alternative. Microbial surfactants are
composed of mostly sugar and fatty acid moieties; possess higher
biodegradability, lower toxicity, present remarkable biological
activities (e.g. antimicrobial, antiviral, anticancer, among others),
and have been reported as ‘‘green’’ candidates for the synthesis
and/or stabilization of nanoparticles [10]. Lately, an increased
interest on biosurfactant-mediated processes has been reported,
mainly due to their potential role on the synthesis of silver nano-
particles and NiO nanorods [10,77].
The biological synthesis of nanoparticles is apparently superior
to the chemical one, however it is important to take into account
that this process is much slower comparing to approaches in which
reducing agents are used. Besides, recovering the nanoparticles
from the bacterial mass or natural extracts is somewhat complex,
hence this is also a shortcoming of the biological synthesis of nano-
particles [10]. In this sense, the microbial surfactants comprise an
interesting and greener alternative to the bacteria- or fungi-medi-
ated synthesis processes, as these molecules reduce the formation
of aggregates due to the electrostatic force of attraction and facili-
tate the uniform morphology of nanoparticles.
Regardless of the well-known potentialities of nanoparticles,
they also present some limitations, as for example their small size
and large surface area that can lead to aggregation, thus making
their handling challenging in liquid and dry forms. Also, nanopar-
ticles may be limited regarding their drug loading and release
capacity. Metal nanoparticle properties including size, morphol-
ogy, stability and physicochemical properties are strongly depen-
dent on the experimental conditions, kinetics of interaction
between metal ions and reducing agents, and adsorption mecha-
nism between the stabilizing agent and the metal nanoparticles
[10]. Therefore, the development of synthesis procedures that
enable controlling the abovementioned properties is highly
desirable [145]. Taking also into account the need to produce sta-
ble nanoparticles for unique applications, e.g. drug delivery [146];
the microbial surfactant-mediated synthesis appears to be a prom-
ising approach.As mentioned, several microbial surfactants have been tested in
the synthesis of nanoparticles. For instance, the rhamnolipids
effect on the synthesis/stabilization of nanozirconia particles has
been reported [87]. However, since pH and temperature affect
the nanoparticles stability, screening and development of new
microbial surfactants that could be stable over a range of pH, tem-
perature and salinity concentrations would be highly advanta-
geous for the synthesis and stabilization of nanoparticles.
Moreover, although the microbial surfactant-mediated processes
are highly effective, these are still not cost-effective. Hence, it is
of utmost importance to develop scalable and economic biopro-
cesses for the production of novel microbial surfactants.
The most efﬁcient method for the fast synthesis of great
amounts of nanoparticles is through chemical reduction [10]. This
method allows manipulating the nanoparticles shapes by changing
the reaction conditions. However, the nanoparticles are unstable
and tend to aggregate into larger structures, thus leading to some
loss of their original characteristics and activity. Moreover, the
reactants used are toxic with potential environmental and health
risks [147]. Therefore, an alternative method to overcome the
chemical reduction limitations and prevent nanoparticles aggrega-
tion is through reverse microemulsion which enables obtaining
uniform and size-controllable nanoparticles [148,149]. The synthe-
sis of spherical nanoparticles in W/O microemulsions remains the
most common surfactant-mediated process. In microemulsions,
the water soluble molecules in the droplet are kept inside and
the droplet functions as a ‘‘reactor’’. By increasing the surfactant
concentration, the size of the droplet is decreased, thereby decreas-
ing the particle size. The water content dissolved in the micro-
emulsion will dictate the morphology and size of the resulting
nanoparticles. Han and collaborators [150] demonstrated the inﬂu-
ence of the molar ratio of water to surfactant on the particle size
distribution and monodispersity. It has been hypothesized that
when the particle size is similar to that of the water pool, the sur-
factant molecules will adsorb on the particle surface to inhibit the
particles from aggregating, thus controlling their size and shape.
For instance, in a microemulsion-mediated borohydride reduction
method, the interactive forces among the reverse micelles lead to
collisions among the micelles that result in the exchange of reac-
tants. Consequently, the monomeric silver nuclei start to form in
the micelles and grow to a size dependent on the water core of
the microemulsion.
Despite all the recent progress in the development of DDS, the
perfect vector remains to be designed. This vector must be able
to overcome the current limitations of such systems, namely
regarding safety, bioavailability and efﬁcacy [13]. Besides, the
release of the drug in a controlled and timely manner is highly
desirable. Although some successful examples have been reported
in the literature on the use of triggered systems [151]; future
research should continue to focus on the design and engineering
of such triggers and switchable systems. Microbial surfactants
have been recognized as versatile and useful molecules for several
applications including targeted drug delivery. Although these mol-
ecules have proven their added value in the development of micro-
emulsion-based drug formulations [5], as well as in the synthesis
of nanoparticles [10], this imminent potential remains unexplored.
Given their low toxicity, high biodegradability and biological activ-
ities, besides their performance in the production of the above-
mentioned DDS, microbial surfactants are promising alternatives
to their chemical counterparts [4]. Besides, being produced by a
number of microorganisms, these molecules present a wide variety
of chemical structures which can be seen as an opportunity for the
design of novel vectors. Moreover, microbial surfactants can poten-
tially be used in triggered and targeted drug delivery. Shim and
collaborators [97] successfully demonstrated the enhanced
delivery of siRNA in HeLa cells using cationic surfactin liposomes.
L.R. Rodrigues / Journal of Colloid and Interface Science 449 (2015) 304–316 315Also, it was found that the surfactin-containing liposomes
improved the speciﬁc silencing of the gene of interest. Additionally,
MEL have also been evaluated for gene delivery, as they could form
thermodynamically stable vesicles [152]. Indeed, MEL-containing
vesicles dramatically increased the transfection efﬁcacy of cationic
liposomes leading to considerably higher levels of gene expression
as compared with lipid cationic-containing commercially available
kits [64,65]. Recently, rhamnolipids from a P. aeruginosa bioﬁlm
were evaluated for their ability to trigger the release of a drug
encapsulated in lipid-polymer coated hybrid nanoparticles [88].
This system enabled triggering the drug release in the vicinity of
the P. aeruginosa colonies, thus improving the nanoparticles anti-
bacterial effectiveness. Moreover, pH-sensitive liposomes contain-
ing rhamnolipids and dioleoylphosphatidylethanolamide (DOPE)
have been described as efﬁcient systems for cytoplasmic delivery
of molecules into cells. DOPE in combination with di-rhamnolipids
formed stable multilamellar and unilamellar liposomes. Acidiﬁcat-
ion of the liposomes led to membrane destabilization, fusion and
release of entrapped aqueous liposomes contents; thus these pH
responsive liposomes represent a promising means to deliver for-
eign substances into living cells in a controlled way [88]. All these
examples strongly support the concept that targeted and triggered
drug release using microbial surfactants can be further explored to
develop superior drug delivery systems.
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